Skip to main content
. 2023 May 19;211(2):219–228. doi: 10.4049/jimmunol.2300077

Table II. TRAEs, SAEs, and DLTs.

Adverse Event Any Grade Grade 1 Grade 2 Grade 3 Grade 4
Any 20 17 13 3 2
Abdominal pain 2 1 1a
Allergic reaction 1 1a
Anemia 8 7 1
Constipation 2 2
Cough 1 1
Diarrhea 2 2
Fatigue 7 6 1
Fever/Chills 5 5b
Hyperglycemia 1 1
Hypoalbuminemia 2 1 1
Hypocalcemia 6 3 3
Hypokalemia 3 3
Hyponatremia 4 4
Hypomagnesemia 2 2
Injection-site reaction 2 1c 1
Leukopenia, not specified 5 3 1 1
Lymphopenia 4 1 3
Nausea 3 3
Neutropenia 7 3 4c 1c
Musculoskeletal pain 3 2 1
Shortness of breath 2 1 1a
Strep throat 1 1
Thrombocytopenia 2 1 1
Upper respiratory infection 1 1

Additional grade 1 events were observed in one patient: alanine aminotransferase increase, aspartate aminotransferase increase, creatinine increase, headache, hypermagnesemia, hypotension, rhinitis, sensory neuropathy, shortness of breath, urinary tract infection, and weight loss.

a

SAEs: hospitalization for abdominal pain (n = 1), unrelated to treatment; hospitalization for shortness of breath (n = 1), unrelated to treatment; and allergic reaction to leukocyte growth factor (n = 1), patient removed from study.

b

Regimen was interrupted (fever [n = 1]).

c

DLTs: neutropenia (n = 3), dose reduced; injection-site reaction (n = 1), therapy discontinued.